StreetInsider.com News Articles

BTIG Reiterates Neutral Rating on MaxCyte Inc. (MXCT)

Mon, 24 Aug 2026 06:17:52 -0400

BTIG analyst Mark Massaro reiterated a Neutral rating on MaxCyte Inc. (NASDAQ: MXCT).

The analyst commented: "In this note, we update our MXCT model following the company's Q2'26 earnings print. MXCT did deliver a slight Q2 beat relative to consensus though reaffirmed its 2026 revenue outlook. MXCT is energized by its recent multi-platform technology license deal signed with Genentech (Roche [RHHBY, Not Rated]) to support multiple cell therapy programs across research, clinical development and manufacturing workflows. Under the agreement, Genentech will gain access to MXCT's ExPERT GTx platform and additional platform technologies that support ex vivo cell engineering applications. This partnership

MaxCyte adds two off-target assays for base editor genome therapies

Wed, 19 Aug 2026 08:06:05 -0400

MaxCyte, Inc. (NASDAQ: MXCT) announced the launch of two off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, designed for use in genome editing therapy development, according to a company press release.

The assays are available through MaxCyte's SeQure service and target adenine and cytosine base editors (ABEs and CBEs). CHANGE-seq-BE is described as a biochemical off-target nomination method for base editors, while ONE-seq-BE is characterized as the only nomination assay for base editors that provides visibility of population-specific genetic variants that may affect off-target activity.

Together, the two assays are intended to give therapeutic developers access to orthogonal nomination methods from a single provider.

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

Wed, 19 Aug 2026 08:05:00 -0400

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).

SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

Wed, 19 Aug 2026 08:05:00 -0400

SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and

Form 10-Q MAXCYTE, INC. For: Jun 30

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921964.html

Form 10-Q MAXCYTE, INC. For: Jun 30

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921964.html

MaxCyte, Inc. (MXCT) Reports In-Line Q2 EPS

Wed, 12 Aug 2026 17:09:37 -0400

MaxCyte, Inc. (NASDAQ: MXCT) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $7.27 million versus the consensus estimate of $6.63 million.

For earnings history and earnings-related data on MaxCyte, Inc. (MXCT) click here.

Form 8-K MAXCYTE, INC. For: Aug 12

Wed, 12 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26913066.html

Form 8-K MAXCYTE, INC. For: Aug 12

Wed, 12 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26913066.html

MaxCyte Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:05:00 -0400

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue
Reiterates Full Year 2026 Guidance
Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board
Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July

ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and

MaxCyte Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:05:00 -0400

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue
Reiterates Full Year 2026 Guidance
Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board
Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July

Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP

Tue, 04 Aug 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260804/26862515.html

Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP

Tue, 04 Aug 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260804/26862515.html

Form SCHEDULE 13G/A MAXCYTE, INC. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:20:00 -0400

si-local-file:///var/storage/secattach/20260729/26834276.html

Form SCHEDULE 13G/A MAXCYTE, INC. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:20:00 -0400

si-local-file:///var/storage/secattach/20260729/26834276.html

MaxCyte signs technology license deal with Genentech for cell therapy

Tue, 21 Jul 2026 08:05:27 -0400

MaxCyte, Inc. (NASDAQ: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to support Genentech's cell therapy development programs, according to a press release dated July 21, 2026.

The agreement grants Genentech access to MaxCyte's ExPERT GTx platform and additional platform technologies spanning research, clinical development, and manufacturing workflows. The license is structured to support multiple programs and enables ex vivo cell engineering applications.

The partnership covers cell engineering workflows from early discovery through current Good Manufacturing Practice (cGMP) manufacturing.

"Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Tue, 21 Jul 2026 08:05:00 -0400

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

The license provides Genentech with access to MaxCyte’s ExPERT GTx^® platform and additional platform technologies across select research, clinical development, and manufacturing

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Tue, 21 Jul 2026 08:05:00 -0400

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows

The license provides Genentech with access to MaxCyte’s ExPERT GTx^® platform and additional platform technologies across select research, clinical development, and manufacturing

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

Wed, 15 Jul 2026 16:05:00 -0400

ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12^th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

Wed, 15 Jul 2026 16:05:00 -0400

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at

Form 4 MAXCYTE, INC. For: Jun 17 Filed by: Johnston John Joseph

Mon, 22 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260622/26673514.html

Form 4 MAXCYTE, INC. For: Jun 17 Filed by: Johnston John Joseph

Mon, 22 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260622/26673514.html

Form 4 MAXCYTE, INC. For: Jun 17 Filed by: Hemrajani Rekha

Mon, 22 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260622/26673494.html

Form 4 MAXCYTE, INC. For: Jun 17 Filed by: Hemrajani Rekha

Mon, 22 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260622/26673494.html

Form 4 MAXCYTE, INC. For: Jun 17 Filed by: Erck Stanley C

Mon, 22 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260622/26673488.html